Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Swiss biotech companies: R & D expenses 2015-2017

Swiss biotech companies' research and development expenses from 2015 to 2017 (in million Swiss francs)*

by Statista Research Department, last edited Jan 23, 2019
Swiss biotech companies: R & D expenses 2015-2017 This statistic show Swiss biotech companies' research and development expenses from 2015 to 2017. In 2016, Swiss biotech companies invested a total of around 1.14 billion Swiss francs into research and development.
Swiss biotech and pharma companies

Swiss biotech companies have increased their research and development (R&D) expenses in recent years, from 1.12 billion Swiss francs in 2015 to 1.39 billion Swiss francs in 2017. The amounts spent by public and private companies were around 568 and 823 million francs, respectively. There are some 240 Swiss companies that use biotechnological technologies to develop products. Many are located around Lake Geneva, the Greater Basel Area, and the Greater Zurich Area.

Swiss company Novartis is one of the world’s largest pharmaceutical companies based on prescription sales, generating 49 billion U.S. dollars in 2017, in comparison, research and development spending totaled about 8.3 billion U.S. dollars. Novartis was established in 1996 when the companies, Ciba-Geigy and Sandoz Laboratories, were merged. Currently, the company is headquartered in Basel and its campus includes works from a variety of artists and architects. Novartis revenues are dominated by its pharmaceutical segment, receiving 33 billion U.S. dollars in 2017, and in comparison, it garnered 6 billion U.S. dollars in the Alcon segment.

Roche, another Swiss company, generated 41.7 billion U.S. dollars from pharmaceutical prescription sales and expended 9.2 billion U.S. dollars on R&D in 2017.
Show more

Swiss biotech companies' research and development expenses from 2015 to 2017 (in million Swiss francs)*

TotalPublic biotech companiesPrivate biotech companies
----
----
----
TotalPublic biotech companiesPrivate biotech companies
----
----
----
Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1.5m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $49 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$588 / Year

Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1.5m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $49 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$588 / Year

Download Settings Share
Download started
Please be patient - this may take a moment
by Statista Research Department, last edited Jan 23, 2019
This statistic show Swiss biotech companies' research and development expenses from 2015 to 2017. In 2016, Swiss biotech companies invested a total of around 1.14 billion Swiss francs into research and development.
Swiss biotech and pharma companies

Swiss biotech companies have increased their research and development (R&D) expenses in recent years, from 1.12 billion Swiss francs in 2015 to 1.39 billion Swiss francs in 2017. The amounts spent by public and private companies were around 568 and 823 million francs, respectively. There are some 240 Swiss companies that use biotechnological technologies to develop products. Many are located around Lake Geneva, the Greater Basel Area, and the Greater Zurich Area.

Swiss company Novartis is one of the world’s largest pharmaceutical companies based on prescription sales, generating 49 billion U.S. dollars in 2017, in comparison, research and development spending totaled about 8.3 billion U.S. dollars. Novartis was established in 1996 when the companies, Ciba-Geigy and Sandoz Laboratories, were merged. Currently, the company is headquartered in Basel and its campus includes works from a variety of artists and architects. Novartis revenues are dominated by its pharmaceutical segment, receiving 33 billion U.S. dollars in 2017, and in comparison, it garnered 6 billion U.S. dollars in the Alcon segment.

Roche, another Swiss company, generated 41.7 billion U.S. dollars from pharmaceutical prescription sales and expended 9.2 billion U.S. dollars on R&D in 2017.
Show more
Statista Accounts: Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom
I think of Statista as Google for researchers. Statista provides you with the information you search for right away.
Dr. Horst Stipp

Dr. Horst Stipp
EVP, Research & Innovation, Advertising Research Foundation

Statistics on "Pharmaceutical trends in Europe"
  • Overview
The most important statistics
  • European Pharmaceutical companies
  • Self-medication market
  • Employment
  • Clinical Trials
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.